Contact this Provider:
- Radiation Oncology
- acoustic neuroma
- adenocarcinoma of the head and neck
- anal cancer
- arteriovenous malformation (avm)
- astrocytoma tumors Show All
- 3d conformal radiation therapy
- balloon breast brachytherapy
- brachytherapy
- chemoradiation
- combined modality therapy Show All
Radiation Oncologist Sean Collins, MD, PhD, is director of the CyberKnife Prostate Program at MedStar Georgetown University Hospital and associate professor of Radiation Medicine at Georgetown University School of Medicine. Dr. Collins joined Georgetown in 2006 after completing his residency in radiation oncology at MedStar Georgetown and the Lombardi Comprehensive Cancer Center and, previously, a surgical internship at the Hospital. In addition to his medical degree, he also holds a doctorate in Biological Chemistry, both from the University of Michigan's Medical Scientist Training Program.
The major focus of Dr. Collins' clinical work is the development of prostate cancer treatment protocols using stereotactic body radiation therapy (SBRT). Patients receiving conventionally fractionated radiation therapy are treated daily for approximately 8 to 9 weeks; based on logistics and life responsibilities, such prolonged treatment courses present unnecessary hardship for patients and their family. To date, Dr. Collins has enrolled more than 500 patients on investigator-initiated, IRB-approved clinical protocols exploring the role of SBRT in prostate cancer treatment. His work has appeared in the American Journal of Clinical Oncology, Radiotherapy and Oncology, International Journal of Radiation Oncology Biology Physics, Cancer Journal and many other scientific publications. He also serves as a reviewer or editorial board member for numerous others, including the New England Journal of Medicine.
Philosophy of Care
"We work as a team to make sure that every patient receives the highest quality, most effective treatment available today. That's especially true for prostate cancer patients, where there are so many options. For us, treating prostate cancer is not only about curing the disease, but assuring each patient's long term quality of life. Toward that end, I establish open communications with my patients, for their ease of access and peace of mind from diagnosis through recovery."
Conditions Treated
- Prostate cancer
- Other genitourinary cancers
- Central nervous system tumors including meningiomas, acoustic neuromas and brain metastases
- Melanoma
- Proton therapy
- CyberKnife stereotactic body radiation therapy (SBRT)
- CyberKnife stereotactic radiosurgery (SRS)
- Intensity-modulated radiation therapy/image-guided radiation therapy (IMRT/IGRT/Rapid Arc)
- Brachytherapy
- Residency Program: MedStar Georgetown University Hospital (2006)
- Internship Program: MedStar Georgetown University Hospital (2002)
- Medical School: University of Michigan School of Medicine (2001)
- Board Certification: American Board of Radiology, Radiation Oncology
- Washingtonian Top Doctor
- Educator of the Year, Association of Residents in Radiation Oncology
- Christenson Award, Biochemistry Research Award, University of Michigan
- Max Tishler Award, Tufts University, Excellence in Chemistry Research
- Phi Beta Kappa Honorary; Tufts University
MyGeorgetownMD - Health Newsletter (Summer 2017 CyberKnife Therapy Targets Prostate Cancer With Fewer Treatments: Five vs. 40
Johnson S.B., Soulos P.R., Shafman T.D., Mantz C.A., Dosoretz A.P., Ross R., Finkelstein S.E., Collins S.P., Suy S., Brower J.V., Ritter M.A., King C.R., Kupelian P.A., Horwitz E.M., Pollack A., Abramowitz M.C., Hallman M.A., Faria S., Gross C.P., Yu J.B. Patient-reported Quality of Life After Stereotactic Body Radiation Therapy vs. Moderate Hypofractionation for Clinically Localized Prostate Cancer. Radiotherapy and Oncology.
Lee, J.Y., Daignault-Newton, S., Heath, G., Scarlett, S., Sanda, M.G., Chang, P., Regan, M.M., Michalski, J.M., Sandler, H.M., Feng, F.Y., Kuban, D.A., Zietman, A., Ciezki, J.P., Kaplan, I.D., Crociani, C., McLaughlin, W.P., Mantz, C.A., Finkelstein, S.E., Suy, S., Collins, S.P., Garin, O., Ferrer, M., Hamstra, D.A., Spratt, D.E. Multinational Prospective Study of Patient Reported Outcomes After Prostate Radiotherapy: Detailed Assessment of Rectal Bleeding. International Journal of Radiation Oncology Biology Physics. 2016
Knoll M.A., Oermann E.K., Yang A.I., Paydar I., Steinberger J., Collins B., Collins S., Ewend M., Kondziolka D. Survival of Patients With Multiple Intracranial Metastases Treated With Stereotactic Radiosurgery: Does the Number of Tumors Matter? American Journal of Clinical Oncology. 2016
Lischalk, J.W., Kaplan, I, Collins, S.P. Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer. Cancer Journal; 22(4):307-313.
Mercado, C., Kress, M.A., Cyr, R.A., Chen, L.N., Yung, T., Bullock, E.G., Lei, S., Collins, B.T., Satinsky, A.N., Harter, K.W, Suy, S., Lynch, J., Dritschilo, A., Collins, S.P. (2016) Intensity Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. Frontiers in Radiation Oncology. 2016
Evans, J., Zhao, G., Daignault, S., Sanda, M., Michalski, J., Sandler, H.M., Kuban D., Ciezki, J., Kaplan, I., Zietman, A., Hembroff, L., Feng, F.Y., Suy, S., Skolarus, T.A., McLaughlin, P.W., Wei, J., Dunn, R.L., Finkelstein, S.E., Mantz, C., Collins, S.P., and Hamstra, D.A. Patient-Reported Quality of Life after Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT), and Brachytherapy. Radiotherapy and Oncology. 2015
King, C.R., Freeman, D, Kaplan, I, Fuller, D., Bolzicco, G., Collins, S.P., Meier, R., Wang, J., Kupelian, P., Steinberg, M. and Katz, A. (2013)Stereotactic Body Radiotherapy for Localized Prostate Cancer: Pooled Analysis of Multi-Institutional Prospective Trials. Radiotherapy and Oncology. 109(2):217-21
King, C.R., Collins, S.P., Fuller, D., Wang, P.C. Kupelian, P., Steinberg, M. and Katz, A. (2013) Health Related Quality of Life after Stereotactic Body Radiotherapy for Localized Prostate Cancer: Results from a Multi-Institutional Consortium of Prospective Trials. International Journal of Radiation Oncology Biology Physics. 87(5):939-45
- MedStar Georgetown University Hospital
